Natural therapy: treatment

Showing posts with label treatment. Show all posts

Thursday, August 15, 2013

Patients With Rare Cancers Want More Shared-decision Making About Their Cancer Treatment

Cancer patients under 55 and those with some rarer types of cancer want more of a say in the decisions made about their treatment, according to new research being published in the British Journal of Cancer today (Wednesday). Recently, several US states have introduced legislation or other policies supporting share-decision making.

The research also shows that ethnic minorities and patients with rectal, ovarian, multiple myeloma and bladder cancers are more likely to feel they aren't being given a big enough say in how they are treated.

Scientists funded by the National Institute for Health Research at the University of Cambridge looked at more than 40,000 responses to the 2010 English National Cancer Patient Experience Survey. More than 70 per cent said they felt suitably involved in decisions about their treatment. But younger patients in particular responded to the survey saying that decisions are made without enough of their personal input.

Dr Anas El Turabi, study author based at the University of Cambridge, said: "Although the overall results are very positive and most patients do feel suitably involved in their treatment decisions, there are distinct groups where this isn't the case and we need to address this. There appears to be a generation gap, possibly because younger patients expect to have more of a say in their treatment than older patients.

"This study should help us to focus on those groups of patients who feel the least involved. This means doctors, nurses and the patients themselves need to work together and build strong relationships that allow them to discuss treatment options in every case. Some patient groups may also need extra support to make sure they're properly involved in making these decisions, such as having a longer consultation with doctors or specialist nurses."

Dr Georgios Lyratzopoulos, study author, said: "Although there are differences between the US and UK healthcare systems, we would expect to find similar variation between American patients with different cancers.

"Additionally, this evidence highlights the importance of studying the experience of cancer patients using large national patient surveys such as in the UK, and we feel similar US-wide surveys of this kind would be very useful in identifying those patients who feel side-lined during decisions around their own treatment for cancer."

Martin Ledwick, head information nurse at Cancer Research UK, said: "All patients should feel entitled to discuss the options available with their doctors and nurses and be given the chance to do so. It's important that they're made to feel more like the co-pilots, rather than the passengers, on their own cancer journeys.

"Doctors want the best possible outcome for you when they're considering the most appropriate treatment but that doesn't mean the treatment will always suit every patient. Being able to talk freely about different options will help patients feel more involved."

Source-Eurekalert

View the original article here

Tuesday, August 6, 2013

Scientists: Sleeping Stem Cells Could Hold Key to Treatment of Aggressive Blood Cancer

by Rukmani Krishna on? August 02, 2013 at 12:02 AM Cancer News Rather than displacing healthy stem cells in the bone marrow as previously believed, the cancer is putting them to sleep to prevent them forming new blood cells, discovers scientists studying an aggressive form of leukaemia. Scientists: Sleeping Stem Cells Could Hold Key to Treatment of Aggressive Blood Cancer
The finding offers the potential that these stem cells could somehow be turned back on, offering a new form of treatment for the condition, called Acute Myeloid Leukaemia (AML). The work was led by scientists at Queen Mary, University of London with the support of Cancer Research UK's London Research Institute.

Around 2,500* people are diagnosed with AML in the UK each year, both young and old. Although AML is curable in some the majority die from this disease.

Normally, the bone marrow produces haematopoietic stem cells which mature into "adult" blood cells. In people with AML the bone marrow is invaded by leukaemic myeloid cells which aren't able to develop into normal functioning blood cells.

The result is that the body does not have enough red blood cells or platelet cells, which can cause symptoms of anaemia, such as tiredness, and increase the risk of excessive bleeding. Patients are also more vulnerable to infection as the white blood cells, which fight bacteria and viruses, are not properly formed.

Dr David Taussig, from the Barts Cancer Institute at Queen Mary, University of London, who led the research, said: "The widely accepted explanation has held that AML causes bone marrow failure by depleting the bone marrow of normal haematopoietic stem cells by killing or displacing them.

"However, we have found that samples of bone marrow in both mice models and patients with AML contain the same, or more, of these normal stem cells than usual. So the cancer isn't getting rid of them, instead it appears to be turning them off so they aren't going on to form healthy blood cells.

"If we can find out how the cancer cells are doing this, we can look at exploiting it to find ways to wake these stem cells up. This is very important as, while the cure rate for younger patients can be around 40 per cent, in older patients it is much lower. The treatments we have, such as chemotherapy and bone marrow transplants, just aren't very successful in this older patient group."

The scientists studied the levels of haematopoietic stem cells (HSC) in the bone marrow of mice transplanted with human AML. They found the numbers of normal mouse HSCs stayed the same, however what did change was that the HSCs were no longer going through the stages of development which finally results in the formation of new blood cells.

The findings were confirmed by the analysis of bone marrow from 16 patients with AML.

Professor Peter Johnson, Cancer Research UK's chief clinician, said: "Although major progress has been made in treating AML over the years, there's still an urgent need for more effective treatments to improve long-term survival. This study takes us an important step forwards in our understanding of what's going on in the bone marrow of people with AML, an area that we have not known enough about previously, and the challenge now is to turn this understanding into new treatments for patients."

Dr Taussig added: "Usually when the body is stressed, the stem cells become very active. For example, if you have a haemorrhage, they will jump into action to produce more new blood cells. The cancer cells are somehow over-riding this and our next phase of work will concentrate on how they are doing this."

Source-Eurekalert

var xmlHttpvar imgpath,imagefunction RefreshImage(ImageId){image=document.getElementById(ImageId);//alert(ImageId);xmlHttp=GetXmlHttpObject();if (xmlHttp==null) { alert ("Your browser does not support AJAX!"); return; } var url="http://www.medindia.net/captcha/captcha.asp";url=url+"?x="+Math.random();imgpath=url;xmlHttp.onreadystatechange=stateChangedReg;xmlHttp.open("GET",url,true);xmlHttp.send(null);} function stateChangedReg(){if (xmlHttp.readyState==4){image.src = imgpath;}}function RequestCode(){xmlHttp=GetXmlHttpObject();if (xmlHttp==null) { alert ("Your browser does not support AJAX!"); return; } var url="http://www.medindia.net/captcha/reqimgvalue.asp";url=url+"?x="+Math.random();xmlHttp.onreadystatechange=stateChangedReq;xmlHttp.open("GET",url,true);xmlHttp.send(null);} function stateChangedReq(){if (xmlHttp.readyState==4){var seccode=xmlHttp.responseText;if(seccode==document.getElementById("scode").value){//alert(seccode + "same value");}else{document.getElementById("scode").value=xmlHttp.responseText;}}}function GetXmlHttpObject(){var xmlHttpNew=null;try { // Firefox, Opera 8.0+, Safari xmlHttpNew=new XMLHttpRequest(); }catch (e) { // Internet Explorer try { xmlHttpNew=new ActiveXObject("Msxml2.XMLHTTP"); } catch (e) { xmlHttpNew=new ActiveXObject("Microsoft.XMLHTTP"); } }return xmlHttpNew;}function GetXmlHttpObject(){var xmlHttp=null;try { // Firefox, Opera 8.0+, Safari xmlHttp=new XMLHttpRequest(); }catch (e) { // Internet Explorer try { xmlHttp=new ActiveXObject("Msxml2.XMLHTTP"); } catch (e) { xmlHttp=new ActiveXObject("Microsoft.XMLHTTP"); } }return xmlHttp;}

function fnsearch(){day1 = document.search.SelDay.value;month1 = document.search.SelMonth.value;year1 = document.search.SelYear.value;tmpdate=month1+"/"+day1+"/"+year1 fromdate=new Date(year1,month1-1,day1)if (!((fromdate.getDate()==day1)&&(fromdate.getMonth()+1==month1)&&(fromdate.getFullYear()==year1))){alert("Please Select a valid Date")document.search.SelDay.focus();return false;}tmpcatid=document.search.ncategoryid.value;tmpkeyword=document.search.keyword.value;document.search.action="http://www.medindia.net/news/newsday_list.asp?ddate="+tmpdate+"&ncategoryid=" +tmpcatid +"&keyword=" +tmpkeywordreturn true;}News Categories:?? Latest Health News Popular News AIDS/HIV News Alcohol & Drug Abuse News Alternative Medicine News Anti-Aging News Bird Flu News Cancer News Celebrity Health News Chikungunya News Child Health News Cholesterol News Clinical Trials News Corporate News Dengue News Dental News Diabetes News Diet & Nutrition News Drug News Education News Environmental Health General News Genetics & Stem Cells News Health Insurance News Heart Disease News Hospital News Hypertension News Indian Health News Lifestyle News Medical Gadgets Medical PDA News Medico Legal News Men?s Health News Mental Health News News on IT in Healthcare Nursing Profession News Obesity News Organ Donation News Research News Respiratory Disease News Senior Health News Sexual Health News Tropical Disease News Weight Loss Women Health News

View the original article here

Monday, August 5, 2013

Scientists Urge Major Changes for Cancer Screening and Treatment

The "Viewpoint" article will be published online Monday, July 29, in the Journal of the American Medical Association.

When cancer screening programs were widely initiated three decades ago, medical knowledge of the disease was more simplistic. The intent was to detect cancer at its earliest stages to reduce illness and mortality, but in fact early diagnosis has not led to a proportional decline in serious disease and death, the scientists write in the JAMA commentary.

Instead, screening programs are identifying not only malignant cancers, but also slow-growing, low-risk lesions, and sweeping them into the same treatment process. As a result, patients are being diagnosed and treated for forms of cancer that might never actually harm them - a phenomenon that''s been termed overdiagnosis, which translates to "too much medicine."

Now, with the advancement of scientific understanding of the biology of cancer, the authors say it is time for significant changes in practice and policy.

"By recognizing that cancer is not one disease, but a number of different diseases, we can individualize our treatment based on biology and avoid overtreatment," said panel chair Laura J. Esserman, MD, MBA, director of the Carol Franc Buck Breast Care Center at the UCSF Helen Diller Family Comprehensive Cancer Center. "The goal going forward is to personalize screening strategies, and focus screening policies on the conditions that are most likely to result in aggressive illness and death."

The authors recommend creation of a new classification for tumors that are indolent (unlikely to cause patients harm). For example, ductal carcinoma of the breast -- currently considered the earliest form of breast cancer -- would no longer be called cancer. The authors also call for the formation of registries for lesions with low potential for malignancy, and for a multidisciplinary approach across pathology, imaging, surgery and other medical specialties "to revise the taxonomy of lesions now called cancer."

The key, they say, is to improve screening strategies to avoid overtreating tumors that would not be lethal, or that would not even have come to medical attention.

"Although our understanding of the biology of cancer has changed dramatically, perceptions on the part of the public, and among many physicians, have not yet changed," Esserman said. "Cancer is still widely perceived as a diagnosis with lethal consequences if left untreated."

The JAMA article is comprised of recommendations from a working group formed last year during a meeting convened by the National Cancer Institute. The group was charged with developing a strategy to improve current approaches to cancer screening and prevention.?

The commentary was co-written by Ian M. Thompson, MD, professor at the University of Texas Health Science Center at San Antonio; and Brian Reid, MD, PhD, director of the Seattle Barrett''s Esophagus Program and member of the Human Biology Division at the Fred Hutchison Cancer Research Center in Seattle.

The three authors served as chairs of the NCI working group.

Overdiagnosis is occurring across many medical conditions, but is particularly common in breast cancer, lung cancer, prostate, thyroid cancer and melanoma, said the authors.

They cite DCIS, or ductal carcinoma of the breast, and Barrett''s esophagus as illustrations of how the detection and surgical removal of what have been called precancerous lesions have failed to lead to lower rates of invasive cancer.

By contrast, the authors said, colon and cervical cancer serve as examples of "effective screening programs in which early detection and removal of precancerous lesions have reduced incidence as well as late-stage disease."?

Cancer screening should have three important missions, the authors write: To detect disease that would ultimately harm the patient; to uncover tumors that benefit from intervention; and to detect disease that is more likely to be cured or better treated when spotted early.

Optimal screening frequency depends on a cancer''s growth rate. If a cancer is fast growing, screening is less likely to be effective. "If a cancer is slow growing but progressive, with a long latency and a precancerous lesion, screening is ideal and less frequent screening (eg.10 years for colonoscopy) may be effective," the authors said.

Source-Newswise

View the original article here

Scientists: Sleeping Stem Cells Could Hold Key to Treatment of Aggressive Blood Cancer

Around 2,500* people are diagnosed with AML in the UK each year, both young and old. Although AML is curable in some the majority die from this disease.

The findings were confirmed by the analysis of bone marrow from 16 patients with AML.

Source-Eurekalert

View the original article here

Wednesday, July 10, 2013

Homicide Rates by Mentally Ill Falls to Lowest Level Thanks to Safer Patient Care and Better Treatment in England

But suicides among mental health patients increased with the current economic difficulties a likely factor.

The findings, reported in the National Confidential Inquiry into Suicide and Homicide by People with Mental Illness (NCI) produced by The University of Manchester, suggest more needs to be done to help mental health patients with debts, housing and employment.

The research team says safety efforts need to focus on patients receiving home treatment where there has been a rise in suicide deaths in recent years. Combined with a fall in the number of inpatient suicides, there are now twice as many suicides under home treatment as in inpatient care.

The report, commissioned by the Healthcare Quality Improvement Partnership on behalf of the NHS England, DHSSPS Northern Ireland, the Scottish Government, the Welsh Government and the Channel Islands, examined homicide and suicide figures for all four countries of the United Kingdom among mental health patients from 2001-2011 (figures for 2011 are provisional).

There were 33 homicides committed by mental health patients in England in 2010 -- the lowest figure since data collection began in 1997 following a peak in 2006. A similar fall was found for homicide by people with schizophrenia in England (22 in 2010) and for people with symptoms of mental illness at the time of offence (England) (36 in 2010)*.

Professor Louis Appleby, Director of the National Confidential Inquiry, said: "It is welcome news that patient homicides are falling and reflects well on the safety measures taken by mental health staff. These are early trends and the precise causes are unknown but they may reflect better care for "dual diagnosis" patients - those with both mental illness and alcohol or drug misuse. The introduction of new Community Treatment Orders may also have played a part."

Provisional figures for suicide showed 1,333 suicides in mental health patients in England in 2011 - up from 1175 in 2010. Patient suicide in Scotland also rose but similar increases in Wales and Northern Ireland were based on small numbers and needed to be treated with caution, researchers said.

Professor Appleby said: "The increase in suicide among mental health patients is in line with an increase in the general population and is mostly likely due to the current economic circumstances. Although these are only early indicators, it would suggest services should try to address the economic difficulties of patients who might be at risk of suicide. Ensuring patients receive advice on debts, housing and employment could make a difference, while improvements in home treatment should now become a priority for suicide prevention. Particular caution is needed with home treatment for patients who live alone or are reluctant to accept treatment."

Other findings in the report include:

Opiates are now the main substances taken by patients in fatal overdoses in all countries; Hanging remains the main method for patient suicides (England, Northern Ireland, Wales).

Source-Eurekalert

View the original article here

Wednesday, June 26, 2013

Potentially Life-saving Cooling Treatment Rarely Used for In-hospital Cardiac Arrests: Researchers

by Rukmani Krishna on? June 25, 2013 at 12:13 AM Heart Disease News Researchers from the Perelman School of Medicine at the University of Pennsylvania report in the June issue of Critical Care Medicine that the brain-preserving cooling treatment known as therapeutic hypothermia is rarely being used in patients who suffer cardiac arrest while in the hospital, despite its proven potential to improve survival and neurological function. The authors suggest that scarce data about in-hospital cardiac arrest patients and guidelines that only call for health care providers to consider use of therapeutic hypothermia, rather than explicitly recommending it, may explain the study's results. Potentially Life-saving Cooling Treatment Rarely Used for In-hospital Cardiac Arrests: Researchers
In a prospective study between 2003 and 2009 of over 530 hospitals in the United States, the Penn team found that 98 percent of over 67,000 patients who went into cardiac arrest in the hospital received only conventional post-resuscitation care--leaving just 2 percent who received therapeutic hypothermia, which has been credited with saving the lives of a growing number of patients who arrest outside hospitals.

"We know it's being used in patients who went into cardiac arrest in their homes, at work, or anywhere else outside of a hospital, but little was known about how often it's used in patients who arrest in the hospital," said Mark E. Mikkelsen, MD, MSCE, assistant professor in the division of Pulmonology, Critical Care and Allergy at Penn Medicine. "We found that even though most hospitals have the capability to treat these patients with therapeutic hypothermia, it's not being used. And even when it was used, in nearly half the cases, the correct target temperature was not being achieved.

"Several factors could explain this: there is little data, which is often conflicting, to support its use for patients in the hospital, and we have national guidelines that only have clinicians considering its use, which may lead to hesitation and lack of institutional protocol."

Cooling the body down to about 89.6 degrees after cardiac arrest protects it against neurological damage initiated by the lack of blood flow and oxygenation, several studies of out-of-hospital cardiac arrest patients have shown. It has also been shown to improve survival--a welcome development, since cardiac arrest survival statistics remain grim, with less than 10 percent of patients surviving in most cities across the U.S.

More than 300,000 people who go into cardiac arrest out of the hospital die each people each year in the United States; thousands of others are left neurologically devastated.

About 210,000 patients a year go into cardiac arrest while in the hospital--many of those patients may have other conditions that point to a poor prognosis, and a substantial portion may be terminally ill patients who are not candidates for hypothermia.

National recommendations established in 2005 call for out-of-hospital cardiac arrest patients to be treated with hypothermia when they remain comatose after resuscitation. In-hospital recommendations, however, are less direct. The International Liaison Committee on Resuscitation guidelines recommend providers to "consider its use," while the American Heart Association recommends that therapeutic hypothermia "may be considered" for a patient who goes into cardiac arrest caused by non-shockable rhythms.

For the study, the team analyzed treatments of 67,498 patients at 538 hospitals participating in the American Heart Association's Get With the Guidelines-Resuscitation database from 2003 to 2009. Of those patients, 1,367 patients were given therapeutic hypothermia. The use of therapeutic hypothermia increased slightly, from 0.7 percent in 2003 to 3.3 percent in 2009.

Younger patients and patients who were treated in a non-ICU location and a teaching hospital were more likely to get therapeutic hypothermia. Even when it was used, however, target temperature (32-34o Celsius, or 89.6-93.2 degrees Fahrenheit ) was not achieved in 44.3 percent of the patients within 24 hours, and 17.6 percent were overcooled.

"These rates are particularly important to examine, given that the incidence of in hospital events appears to be increasing," said Dr. Mikkelsen. "I believe there is potential for therapeutic hypothermia to benefit this population, but traction can only be made after clinical trials investigating safety and effectiveness are initiated-which are certainly warranted. Results of those studies could strengthen the case for stronger recommendations and increase use."

Source-Eurekalert

View the original article here

Monday, June 24, 2013

Tocilizumab effective in the treatment of arthritis juvenile idiopathic

Tocilizumab is a recombinant, humanized antibody that blocks receptors where Interleukin 6 (IL-6) is attached to the surface of the cells. 6 - It is impossible to attach to these cells, they are banned from lead to inflammation. Serum and joint fluid IL-6 levels were shown to be associated with the activity of the disease in patients with pcJIA.1

"JIA is a chronic arthritis in 1 child per 1,000. Without apparent cause, it can lead to joint damage and permanent disability. "These data demonstrate that tocilizumab improves rapidly of the signs and symptoms of pcJIA, with significant, maintained clinical responses in a large proportion of patients at week 40," said author Dr. Fabrizio De Benedetti of the Pediatric IRCCS Ospedale Bambino Gesu, Rome.

Speaking on behalf of the Paediatric Rheumatology International Trials Organization (Florence) and pediatric Rheumatology Collaborative Study Group (PRCSG), who supervised the study, Mr. De Benedetti has concluded that "these data suggest that tocilizumab is going to be a partly biological novel of the therapeutic arsenal for pcJIA."

CHERISH is a two year trial, 3 - part implemented in 58 centres in 15 countries. Patients aged 2-17 years were included in the study if they had pcJIA active for at least 6 months and had not responded to methotrexate (a cornerstone of therapy in the world for this condition).

Part 1 of the study was an open 16-week phase in which 188 patients received tocilizumab every four weeks. 166 Patients who have reached at least a 30% improvement in signs and symptoms of pcJIA (JIA ACR30 response *) were then part 2, which was a 24-week study in which patients were randomized to continue on the same dose of tocilizumab or receiving a placebo. Part 3 is a study in an ongoing open.

For primary point of end ACR30 rounded, fewer patients in tocilizumab group than in the placebo group experienced a flare of the week 40 (25.6% versus 48.1%) and JIA ACR30/50/70 * responses were significantly higher with tocilizumab than placebo, with up to 65% of children achieving an ACR70 response.

Determination of tocilizumab was based on the body weight of the patient (BW): with a BW 30 kg, the dose was 8 mg/kg [n = 119]; with a BW<30 kg,="" patients="" were="" randomly="" assigned="" to="" 8="" mg/kg="" [n="34]" or="" 10="" mg/kg="" [n="35].">

"The degree of improvement at week 16 was lower for each of the endpoints for patients under the age of 30 kg on tocilizumab 8 mg/kg than in the other two groups." The data therefore support the efficacy of tocilizumab in pcJIA by using a monthly scheme at doses of 8 mg/kg if BW 30 kg or more and 10 mg/kg if BW less than 30 kg, "said Benedetti.

The patients were also taking background medications, such as methotrexate and oral corticosteroids (respectively 79% versus 46%).

Tocilizumab safety profile was consistent with that of the other patients.2 tocilizumab treated with data security hack, 184 patients years of follow-up were produced in 188 patients recruited. The infection was the most common adverse event (164/100 patient years) and adverse events serious (4.9/100 patient years). Liver enzymes (ALT/AST) elevation 3 upper limit of normal occurred at 3.7%.<1% of="" patients,="" neutropenia=""><1000 cells/mm3)="" in="" 3.7%="" of="" patients,="" thrombocytopenia=""><50,000 cells/mm3)="" in="" 1.1%="" of="" patients.="" an="" elevation="" of="" ldl-cholesterol="" ??110="" mg/dl="" was="" reported="" in="" 11.4%="" of="" patients="" who="" received="" tocilizumab.="">

Source-Eurekalert

View the original article here

Thursday, May 23, 2013

New Analysis to Predict Efficacy of Breast Cancer Treatment

by Dr.Enozia Vakil on? May 04, 2013 at 11:35 AM Cancer News A new analysis may help better determine which women with oestrogen-receptor positive breast cancer are at a risk of recurrence, and which ones benefit from endocrine treatment. New Analysis to Predict Efficacy of Breast Cancer Treatment
The promising new findings will likely benefit the many women with oestrogen-receptor positive breast cancer whose cancer recurs more than five years after diagnosis, researchers told the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium.

The IMPAKT meeting presents cutting edge, 'translational' breast cancer research that is beginning to have an impact for patients.

In oestrogen-receptor positive women, half of all recurrences of breast cancer will occur after the women finish the standard 5 years of hormonal treatment, explains lead author Dr Ivana Sestak from the Wolfson Institute of Preventive Medicine in London, UK.

"There is great interest in establishing which women are at adequate high risk of late recurrence after the initial hormonal treatment period, which is currently 5 years," Dr Sestak says.

At the meeting, researchers reported the findings of a comparison of five different scores designed to predict which women may be at increased risk of developing a late recurrence of their cancer. This is the first time that all five scores have been compared within one dataset.

Knowing which women may be at increased risk of developing a late recurrence would enable doctors to identify those women who may be good candidates for extended hormonal therapy, she says.

The ATAC trial included nearly 10,000 women who were treated with surgery followed by five years of treatment with the drugs anastrozole, tamoxifen or a combination of both. Of these 1,125 from the monotherapy arms (tamoxifen, anastrozole) were included in the transATAC study.

The five scores being compared were the: Clinical Treatment Score, which includes information on the patient's disease and treatments so far; IHC4 score, which characterises the presence of cell surface markers on cancer cells; Three different gene expression scores -- the Oncotype Dx Recurrence Score; the PAM50 Risk of Recurrence Score; and the Breast Cancer Index score. The results showed that the clinical treatment score alone was the best for predicting late recurrence, the researchers report. The components of this score include some that are already widely used by doctors, such as whether the cancer has spread to sentinel lymph nodes, the tumour size and grade.

Among the other tests, the PAM50 risk of recurrence score and the Breast Cancer Index score added the most significant prognostic value between years 5 and 10 after diagnosis.

"The most promising new scores from this study are the PAM50 Risk of Recurrence score and the Breast Cancer Index score, both containing different genetic information that are not included in the clinical treatment score and at the moment not routinely measured in clinics," Dr Sestak says.

"Our further interest now lies in the investigation of which individual components of these scores attribute specifically to the prediction of late recurrence, since the Risk of Recurrence and Breast Cancer Index scores consist of several genes and other components. We are now undertaking these analyses and the results will hopefully tell us which genes specifically predict late recurrence. However, at this stage it is not possible to predict response to treatment."

Commenting on the results, Dr Peter Dubsky from the Medical University of Vienna, Austria, noted that oestrogen-receptor positive and Her2 negative breast cancers are prone to late recurrences.

"About half of all recurrences observed within 15 years of follow-up occur five years after diagnosis. Although there is a sustained benefit of adjuvant endocrine therapy beyond five years, we still see two-thirds of breast cancer deaths occurring after this time. Clearly, the identification of women that are at risk for these late types of recurrences is an important clinical research goal," said Dr Dubsky, who was not involved in the study.

"Sestak and colleagues provide highly relevant new data to meet this end: they have compared five different prognostic scores in order to predict outcome beyond the first five years of follow-up. Of note, none of these scores were primarily trained to specifically predict late recurrence. They show that a Clinical Treatment score (CTS) contained most of the prognostic information relevant to late distant metastases. Interestingly, only the Risk of Recurrence (ROR) score (PAM50) and the Breast Cancer Index (BCI) score provided additional information to the CTS. This data will need further validation before actually being incorporated into clinical decision-making concerning adjuvant endocrine therapy beyond five years."

These findings are similar to those proposed by the Austrian Breast and Colorectal Cancer Study Group recently, Dr Dubsky said. "The Endopredict Score was able to add additional prognostic information to clinical variables concerning distant metastases occurring later than five years after diagnosis. Future research should further address which are the biologic motifs behind late recurrences. Furthermore, molecular tools specifically designed to predict late metastasis should be developed."

Source-Eurekalert

View the original article here

Wednesday, May 8, 2013

Home treatment eczema

Eczema home treatment Atopic Dermatitis eczema is a condition in which the skin becomes porous and dry and inflamed when exposed to certain irritants and allergens. It includes: exposure to cold and wet climates, contact with some materials such as wool and rubber, residues of detergents, foods allergens, dust mites, etc.

A combined treatment eczema at home should merge the conventional dermatological treatments psychological and lifestyle changes that seek to eliminate the recurrence of flare ups and self-damaging behavior of scratching which aggravates atopic dermatitis.

Click here for 100% natural eczema treatment.

According to studies, 25% of the world population suffers from atopy - the rule of law related to vulnerability to develop astma, hay fever and eczema atopic dermatitis at various stages in life. Lifestyle changes key necessary to keep these controlled conditions, seek to identify and eliminate common aggravating factors:

1. Dust mites
Eczema home treatment Western modern life is associated with a high allergen concentration taken trapped in modern housing: the fecal pellets of mites and mite itself, which feeds to throw human skin. The following measures are effective in limiting exposure to dust mites:

Vacuum regularly, every day, because this removes up to 70% of dust mites, especially if you use a specialized astma allergy vacuum cleaner andwash bedding regularly, at least once a week, using 60 ° C or higher wash temperature, as dust, mites are killed in high extreme or of low temperaturesPut cloth in the freezer toys each weekpolished floors that can be used regularly are preferred instead of carpetwhich are a breeding ground for mites

2. The dander
Limiting the exposure of the baby to the pets in general and try to avoid having an internal fur animal, such as epidermal cells (dander) discharged by domestic animals i.e. cats and dogs is difficult to remove, even if you regularly clean.

3 Food allergies
Studies suggest that atopic dermatitis and allergies play a role in the development and exacerbation of the other. Eczema home treatment should aim to eliminate the most common food allergens of feeding baby and see if you notice an improvement in the condition of eczema: dairy products, wheat, peanuts, etc.

4 Detergent residue on clothes
Detergent residual laundry in clothes may be irritating, so using a luquid rather than powdered detergent and adding a second rinse cycle to facilitate the operation of detergent is perhaps useful. New clothing should be laundered before wearing to remove formaldehyde and other chemichals. Make sure you use a biological baby hypoallergenic detergent for washing clothes and the baby bedding and do not use bleach or fabric softener for textiles.

5. The chemicals found in cosmetics and soaps; water hardness
Normal appearing in patients with atopic dermatitis eczema of the skin is in fact abnormal, suffering from a loss of water by diffusion 7 days after being exposed to an irritating topical. Neutral PH, rather than soaps cleansers should be used sparingly. Alcohol and astringents, found in skin care products can be drying and exposure to water should be reduced to the minimum.

6. Loss of hydration of the skin
Atopic Dermatitis eczema is possible through a skin barrier allowing epidermal water loss and the penetration of irritants and allergens that trigger pruritus. The mechanical trauma of scraping even exacerbates atopic skin inflammation. Treatment eczema at home aims to prevent the onset of the first symptoms of hydrating the skin with specially formulated cream lotions.

7 MICROAIR DermaSilk

This silk knitted breathable and slightly elastic is effective for acute lesions of atopic dermatitis, as it is treated with an antimicrobial finish the water which prevents the survival of bacteria-resistant

Click here for 100% natural eczema treatment.

Eczema Free Forever